Techcyte Analysis: $25M Raised
What is Techcyte?
Techcyte is an AI software platform specializing in anatomic and clinical pathology. It leverages machine learning to enhance diagnostic efficiency and accuracy for laboratories and patients. This innovative approach transforms traditional pathology workflows, enabling quicker and more reliable diagnoses.
Employees
51-200
Founded
2013
Industry
HealthTech, AI/ML, Data Analytics
Latest Funding Round Size
Series A
Parent Company Website
Public Company Status
Private
Recent Venture Round Amount
$21,000,000
Product Features & Capabilities
- Techcyte Fusion digital pathology platform
- Fusion AP for anatomic pathology
- Fusion Frozen Section Suite for rapid diagnostics
- Techcyte SureView Cervical Cytology System
- Fusion Bacteriology Suite for microbiology analysis.
Use Cases
Streamline pathology workflows using AI-driven solutions; Enhance diagnostic accuracy in clinical laboratories; Improve efficiency in anatomic pathology processes; Facilitate rapid diagnosis with frozen section analysis; Automate cervical cytology assessments for better patient outcomes.
How much Techcyte raised
Series A - $21 million
August 18, 2021Lead Investor: Zoetis, ARUP Laboratories, and previous investors.
Seed - $4.3 million
Lead Investor: Not specified
Other Considerations
CE-IVDD marked in Europe; Collaborations with Mayo Clinic and BD; Founded in 2013, focusing on digital diagnostics.
